文献速递甲状腺疾病垂体与肾上腺疾病

左甲状腺素治疗心力衰竭患者的长期结局:全国性观察性队列研究

Long-Term Outcome in Patients With Heart Failure Treated With Levothyroxine: An Observational Nationwide Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

这项回顾性全国队列研究纳入1997至2012年丹麦≥18岁心衰患者224,670例,其中基线时已用左甲状腺素(L-T4)者6560例、随访中新启用者9007例。中位随访4.8年,持续用药与新启用L-T4均与全因死亡、心血管死亡和主要不良心血管事件风险升高相关;心肌梗死风险在持续用药者升高、新启用者降低。

要点

  • 心衰患者持续或新启用L-T4均与全因死亡、心血管死亡及MACE风险升高相关。
  • 持续L-T4治疗与心肌梗死风险升高相关,而新启用治疗与心肌梗死风险降低相关。
  • 该观察性研究提示心衰患者L-T4治疗需审慎评估,不能直接推断因果。

核心结论

  • 心衰患者持续或新启用L-T4治疗与全因死亡、心血管死亡和MACE风险升高相关。
  • 持续L-T4治疗与心肌梗死风险升高相关,新启用L-T4治疗与心肌梗死风险降低相关。

研究设计与样本

  • 回顾性全国性观察性队列研究,纳入1997至2012年丹麦所有≥18岁确诊心衰的公民。
  • 共224,670例心衰患者,平均年龄70.7岁(SD±14.7),53%为男性。
  • 基线时6560例接受L-T4治疗,随访中9007例新启用L-T4,209,103例未接受L-T4。
  • 采用泊松回归模型计算发生率比(IRR)。

主要发现

  • 中位随访4.8年(IQR 9.2),147,253例患者死亡。
  • 基线时持续L-T4治疗者全因死亡IRR 1.25(95%CI 1.21–1.29),新启用者IRR 1.13(95%CI 1.10–1.16)。
  • 基线时持续L-T4治疗者心血管死亡IRR 1.23(95%CI 1.18–1.27),新启用者IRR 1.11(95%CI 1.08–1.15)。
  • 基线时持续L-T4治疗者MACE IRR 1.26(95%CI 1.22–1.31),新启用者IRR 1.05(95%CI 1.02–1.09)。
  • 持续L-T4治疗者心肌梗死IRR 1.32(95%CI 1.23–1.41),新启用者IRR 0.87(95%CI 0.81–0.93)。

临床怎么用

  • 心衰患者启用或维持L-T4治疗时,应结合甲状腺功能状态个体化评估心血管获益与风险。
  • 对心衰患者新启用L-T4后需关注全因死亡、心血管死亡及MACE风险,并监测心肌梗死。

局限性

  • 回顾性观察性设计,不能确立L-T4治疗与不良结局之间的因果关系。
  • L-T4治疗信息来自全国登记系统,可能存在适应证混杂和残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hypothyroidism has detrimental effects on the cardiovascular system, but controversy remains concerning the benefits of levothyroxine (L-T4) substitution in patients with heart failure (HF). OBJECTIVE: Examining the effects of L-T4 in patients with HF. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: All Danish citizens aged ≥18 years diagnosed with HF between 1997 and 2012. L-T4 treatment was identified from nationwide registers. Incidence rate ratios (IRRs) were calculated with Poisson regression models. MAIN OUTCOME MEASURES: All-cause mortality, myocardial infarction (MI), cardiovascular death, and major adverse cardiovascular events (MACEs). RESULTS: A total of 224,670 patients were diagnosed with HF [mean age 70.7 (SD ± 14.7) years, 53% male]. Of these, 6560 patients were treated with L-T4 at baseline, and 9007 patients initiated L-T4 during follow-up. A total of 209,103 patients did not receive L-T4. During a median follow-up of 4.8 years [interquartile range (IQR) 9.2] 147,253 patients died. Increased risk of all-cause mortality (IRR 1.25; 95% CI, 1.21 to 1.29; IRR 1.13; 95% CI, 1.10 to 1.16), cardiovascular death (IRR 1.23; 95% CI, 1.18 to 1.27; IRR 1.11; 95% CI, 1.08 to 1.15), and MACE (IRR 1.26; 95% CI, 1.22 to 1.31; IRR 1.05; 95% CI, 1.02 to 1.09) was observed for treatment ongoing at baseline and initiated during follow-up, respectively. Increased risk of MI (IRR 1.32; 95% CI, 1.23 to 1.41) was observed for ongoing treatment, and reduced risk (IRR 0.87; 95% CI, 0.81 to 0.93) was observed for incident treatment. CONCLUSION: Ongoing and incident L-T4 treatment in patients with HF was associated with an increased risk of all-cause mortality, cardiovascular death, and MACE. Increased risk of MI was observed for ongoing treatment, and reduced risk was observed for incident treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Einfeldt MN, Olsen AS, Kristensen SL, et al. Long-Term Outcome in Patients With Heart Failure Treated With Levothyroxine: An Observational Nationwide Cohort Study. J Clin Endocrinol Metab. 2019. PMID: 30517746. doi:10.1210/jc.2018-01604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。